This study, conducted in East Asia, included patients aged 18 and over with visual impairment due to active choroidal neovascularization secondary to pathological myopia with spherical equivalence of ≥ −6D, or an axial length ≥26.5 mm. Activity of CNV lesions was confirmed on fluorescein angiography. Exclusion criteria included: one functional eye, recurrent myopic CNV, ocular inflammation, iris neovascularization, uncontrolled glaucoma or previous trabeculectomy. Predefined retreatment criteria for the aflibercept group (to a maximum frequency of 4-weekly) were: (1) loss of ≥5 ETDRS letters from previous visit (2) Increase in central retinal thickness ≥50 µm, or other OCT changes consistent with activity (3) investigator discretion. These criteria were applied to the control group from week 24 to 44. Note that the control group did not receive any intervention except for sham injections until week 24. The paper does not present statistical comparisons in adverse events between treatment groups.
CNV – choroidal neovascularisation; BCVA – best corrected visual acuity; ETDRS – early treatment diabetic retinopathy study; PRN –pro re nata (i.e. as needed); CRT – central retinal thickness (on optical coherence tomography imaging); µm – micrometres.
Reference: Ikuno et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study”. Ophthalmology, 2015. 122(6):1220–7.
Funding
Medical Research Council UK (MR/R000735/1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yusuf, I.H., Henein, C. & Sivaprasad, S. Infographic: Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Eye (2023). https://doi.org/10.1038/s41433-023-02393-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-023-02393-3